How to Get Evenity (Romosozumab) in New Mexico

What Is Romosozumab and Why Does It Matter for Osteoporosis?

Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein produced by osteocytes that suppresses bone formation. By blocking sclerostin, romosozumab simultaneously stimulates new bone formation and reduces bone resorption. This dual mechanism is unique among osteoporosis therapies. The FDA approved Evenity in April 2019 for postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or failure of other osteoporosis therapies.

In the ARCH trial (N=4,093), romosozumab reduced new vertebral fractures by 48% compared with alendronate at 24 months. The same trial showed a 38% lower risk of clinical fractures in the romosozumab-to-denosumab sequence versus alendronate-to-alendronate [1]. These results placed romosozumab among the most effective anabolic agents available for severe osteoporosis.

The drug carries a black box warning for cardiovascular risk, so prescribers in New Mexico must evaluate patients for recent myocardial infarction or stroke within the preceding year before initiating treatment [2]. The 12-dose course is finite. After completion, patients transition to an antiresorptive agent (typically denosumab or a bisphosphonate) to maintain gains in bone mineral density.

Who Can Prescribe Evenity in New Mexico?

Any provider with prescriptive authority in New Mexico can write a romosozumab prescription: MDs, DOs, nurse practitioners, and physician assistants. New Mexico grants NPs full practice authority without a collaborative agreement, making NP-led osteoporosis clinics a realistic access point for rural patients [3].

Specialty matters less than clinical competency. Rheumatologists, endocrinologists, and orthopedic surgeons prescribe Evenity most frequently, but primary care providers comfortable with DXA interpretation and fracture risk assessment can also initiate therapy. Telehealth-licensed prescribers in New Mexico can evaluate patients remotely and order the necessary labs and imaging before prescribing. The prescriber must be licensed in New Mexico or hold an active interstate compact license recognized by the state.

Telehealth Access to Romosozumab in New Mexico

New Mexico permits telehealth prescribing of romosozumab. The state's Telehealth Act requires that the provider hold an active NM license and establish a provider-patient relationship, which can happen entirely via a synchronous video visit. No in-person visit is required before prescribing.

A typical telehealth pathway works like this. The patient completes an intake that includes medical history, fracture history, and cardiovascular screening. The provider orders a DXA scan at a local imaging center and reviews baseline labs (serum calcium, 25-hydroxyvitamin D, renal function, and cardiac history). Once results confirm eligibility and the provider rules out cardiovascular contraindications, they submit the prescription and prior authorization paperwork. The actual injection still requires a clinical setting, since romosozumab is administered subcutaneously by a healthcare professional in most cases, though some patients self-inject after training.

Rural counties in New Mexico, including those with no local endocrinologist within 100 miles, benefit from telehealth-initiated prescribing paired with local injection sites. Infusion centers in Albuquerque, Las Cruces, and Santa Fe can administer the monthly dose after a telehealth provider manages the prescription remotely.

Labs and Diagnostic Workup Before Starting Evenity

Prescribers require specific documentation before initiating romosozumab. A DXA scan showing a T-score of <-2.5 at the lumbar spine, femoral neck, or total hip confirms osteoporosis [4]. The Endocrine Society's 2020 guidelines recommend DXA as the gold standard for diagnosis, and most insurers in New Mexico require it for prior authorization.

Baseline labs should include:

• Serum calcium (to rule out hypocalcemia, which must be corrected before starting romosozumab)
• 25-hydroxyvitamin D (target >30 ng/mL; supplement if deficient)
• Serum creatinine and eGFR (romosozumab is not renally cleared, but renal status informs overall fracture risk)
• CBC and comprehensive metabolic panel
• Cardiovascular screening: ECG and review of cardiac history per the black box warning

The AACE 2020 clinical practice guidelines recommend romosozumab as first-line therapy for patients at very high fracture risk, defined as a recent osteoporotic fracture within the past 12 months, a T-score of <-3.0, or a high FRAX score [5]. Documenting "very high risk" status in the chart strengthens the prior authorization submission.

Insurance Coverage and Prior Authorization in New Mexico

This is where the process gets complicated. New Mexico Medicaid does not cover romosozumab as of 2026. Patients on Medicaid who need anabolic therapy may be limited to teriparatide (Forteo) or abaloparatide (Tymlos), both of which have different Medicaid formulary statuses depending on the managed care organization.

Commercial insurers in New Mexico (Blue Cross Blue Shield of NM, Presbyterian Health Plan, Molina, Western Sky) typically cover Evenity under specialty pharmacy or medical benefit, but require prior authorization. The standard documentation package includes:

1. DXA scan confirming T-score <-2.5
2. Documentation of high or very high fracture risk (FRAX score or prior fracture history)
3. Failure of or contraindication to at least one bisphosphonate (step therapy requirement)
4. Cardiovascular risk assessment confirming no MI or stroke in the past 12 months
5. Prescriber's letter of medical necessity

Medicare Part B covers romosozumab as a "buy-and-bill" drug administered in a provider's office, using HCPCS code J3111. The provider purchases the drug, administers it, and bills Medicare directly. Prior authorization under Medicare typically requires the same clinical documentation listed above [6].

Denial rates for romosozumab prior authorization run high on first submission. Appeals succeed more often when the prescriber includes the FRAX 10-year hip fracture probability (a threshold above 3% strengthens the case) and documents bisphosphonate intolerance with specific adverse events rather than vague statements.

Pharmacy and Drug Acquisition in New Mexico

Romosozumab is a biologic monoclonal antibody. It cannot be compounded by 503A pharmacies. Patients who see references to 503A compounding availability in New Mexico should understand that this applies to other medications, not to Evenity.

The drug is distributed through specialty pharmacies. Amgen's Evenity Support Program connects patients with specialty pharmacy fulfillment and copay assistance. Major specialty pharmacies operating in New Mexico include CVS Specialty, Accredo (Express Scripts), and Optum Specialty Pharmacy.

For buy-and-bill through Medicare Part B, the prescribing clinic purchases Evenity directly from a specialty distributor (McKesson, AmerisourceBergen, or Cardinal Health) and stores it according to the cold chain requirements (2°C to 8°C). The drug ships as two prefilled syringes per dose, each containing 105 mg/1.17 mL, administered as two separate subcutaneous injections in the abdomen, thigh, or upper arm [7].

Patients without insurance can explore Amgen's patient assistance program, which provides Evenity at no cost for qualifying individuals with household income below 300% of the federal poverty level. The application requires income verification and a signed prescription.

Cost of Evenity in New Mexico

The wholesale acquisition cost (WAC) for a single monthly dose of romosozumab is approximately $1,825. Over the full 12-month course, that totals roughly $21,900 before insurance. Out-of-pocket costs vary widely.

With commercial insurance and a specialty tier copay, patients may pay $100 to $500 per month depending on plan design. Amgen's copay card can reduce this to as low as $0 for eligible commercially insured patients. Medicare Part B patients typically pay 20% coinsurance after the Part B deductible, which amounts to approximately $365 per injection without supplemental coverage [8].

The ARCH trial's demonstrated fracture reduction (48% fewer vertebral fractures vs. alendronate at 24 months) supports the cost-effectiveness argument that prescribers can include in appeals. A 2021 cost-effectiveness analysis published in the Journal of Bone and Mineral Research found romosozumab-to-alendronate was cost-effective at a willingness-to-pay threshold of $150,000 per quality-adjusted life year in patients at very high fracture risk [9].

Timeline: How Long From Consultation to First Injection

Expect four to eight weeks from the initial telehealth consultation to the first romosozumab injection in New Mexico. Here is a realistic breakdown.

Week 1: Telehealth intake, lab orders, and DXA scan scheduling. DXA availability in Albuquerque is typically within 5 to 10 business days. In rural areas (Gallup, Farmington, Roswell), wait times may extend to 2 to 3 weeks.

Weeks 2 to 3: Lab results and DXA reviewed. Prescriber confirms eligibility and submits prior authorization.

Weeks 3 to 5: Prior authorization review. Commercial insurers in New Mexico must respond to standard prior authorization requests within 15 business days under NMAC 13.10.17.11. Urgent requests receive a 24-hour turnaround.

Weeks 5 to 6: Specialty pharmacy receives approved prescription, conducts benefits investigation, and ships drug to the administering clinic or arranges buy-and-bill fulfillment.

Weeks 6 to 8: First injection administered in a clinical setting.

Delays most commonly occur at the prior authorization stage. A clean submission with all required documentation (DXA, FRAX, bisphosphonate history, CV clearance) on the first attempt avoids the most frequent bottleneck.

Cardiovascular Safety Considerations

The black box warning on Evenity is not a formality. In the ARCH trial, the romosozumab group had a higher rate of serious cardiovascular events compared with the alendronate group during the first 12 months (2.5% vs. 1.9%) [1]. The FDA's 2019 review specifically noted an imbalance in adjudicated major adverse cardiovascular events (MACE), including cardiovascular death, nonfatal MI, and nonfatal stroke [2].

New Mexico prescribers should not initiate romosozumab in patients who have had an MI or stroke within the past year. Patients with uncontrolled hypertension, established atherosclerotic cardiovascular disease, or multiple cardiovascular risk factors warrant a cardiology consultation before starting therapy. The American Association of Clinical Endocrinology (AACE) recommends cardiovascular risk stratification as part of the pre-treatment evaluation for all romosozumab candidates [5].

Dr. Felicia Cosman, professor of medicine at Columbia University and lead investigator on the FRAME trial, has stated: "Romosozumab should be reserved for patients whose fracture risk clearly outweighs their cardiovascular risk. The benefit-risk calculus is favorable in the right patient, but it demands careful screening."

The Endocrine Society's 2020 guidelines echo this position: "In patients at very high fracture risk without recent cardiovascular events, romosozumab represents a first-line anabolic option with the strongest vertebral fracture reduction data available" [4].

What Happens After the 12-Month Course

Romosozumab is prescribed for exactly 12 monthly doses. Bone mineral density gains peak during this window and begin to decline if no antiresorptive therapy follows. The FRAME extension study showed that patients who transitioned from romosozumab to denosumab maintained and extended BMD gains, reaching a 17.6% increase at the lumbar spine by month 36, while those transitioned to placebo lost roughly half their gains [10].

The two standard transition protocols used by New Mexico prescribers are:

Romosozumab to denosumab: Most common. Denosumab (Prolia) 60 mg subcutaneously every 6 months, started within one month of the final romosozumab dose. This preserves the anabolic gains and adds antiresorptive protection.

Romosozumab to oral bisphosphonate: An alternative for patients who prefer oral therapy or have concerns about long-term denosumab use and its rebound vertebral fracture risk on discontinuation. Alendronate 70 mg weekly or risedronate 150 mg monthly are the typical choices.

A follow-up DXA scan 12 months after completing romosozumab documents treatment response and informs the next phase of therapy.

Transferring an Existing Romosozumab Prescription to New Mexico

Patients relocating to New Mexico mid-treatment can transfer their romosozumab prescription. The process requires a New Mexico-licensed prescriber to accept the transfer, review the original prescriber's records, and re-submit prior authorization to the patient's insurer (since insurance networks and formulary criteria may differ by state).

Specialty pharmacy transfers are straightforward if the patient remains on the same insurance plan. The specialty pharmacy coordinator can redirect shipments to a new administering clinic in New Mexico. If insurance changes due to the move, a new prior authorization is required, and patients should plan for a 2 to 4 week gap. Maintaining injection timing (every 28 to 35 days) is recommended to preserve treatment continuity, so starting the transfer process before the move is ideal.